Ajanta Pharma Limited (NSE:AJANTPHARM)
India · Delayed Price · Currency is INR 3,327.00
+7.40 (0.22%)
Nov 12, 2026, 3:29 PM IST
Ajanta Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 62,166 | 54,529 | 46,481 | 42,087 | 37,426 | 33,410 | |
Revenue Growth | 25.01% | 17.31% | 10.44% | 12.45% | 12.02% | 15.62% |
Cost of Revenue | 13,842 | 12,639 | 11,429 | 11,210 | 11,102 | 8,840 |
Gross Profit | 48,324 | 41,889 | 35,052 | 30,877 | 26,324 | 24,570 |
Selling, General & Admin | 14,455 | 13,007 | 11,048 | 9,122 | 7,978 | 6,571 |
Other Operating Expenses | 16,357 | 13,885 | 11,279 | 9,944 | 10,241 | 8,667 |
Operating Expenses | 32,621 | 28,623 | 23,768 | 20,420 | 19,527 | 16,491 |
Operating Income | 15,703 | 13,266 | 11,285 | 10,457 | 6,798 | 8,079 |
Interest Expense | -128.8 | -161.1 | -207.3 | -72.1 | -58.4 | -102 |
Interest & Investment Income | 516 | 516 | 471.6 | 277.1 | 84.6 | 146.5 |
Currency Exchange Gain (Loss) | 1,578 | 971.7 | 282.1 | 158.7 | 660.7 | 563.7 |
Other Non Operating Income (Expenses) | 155.5 | 130.5 | 41.4 | 264.1 | 61.5 | 323.8 |
EBT Excluding Unusual Items | 17,823 | 14,723 | 11,872 | 11,084 | 7,546 | 9,011 |
Gain (Loss) on Sale of Investments | -927.9 | -927.9 | 25.2 | 20.1 | -40 | 122.8 |
Gain (Loss) on Sale of Assets | -18.7 | -18.7 | -6 | 34.9 | -53.5 | -38.7 |
Pretax Income | 16,877 | 13,777 | 11,892 | 11,139 | 7,453 | 9,095 |
Income Tax Expense | 4,248 | 3,217 | 2,688 | 2,978 | 1,573 | 1,968 |
Net Income | 12,628 | 10,560 | 9,204 | 8,162 | 5,880 | 7,127 |
Net Income to Common | 12,628 | 10,560 | 9,204 | 8,162 | 5,880 | 7,127 |
Net Income Growth | 29.70% | 14.73% | 12.77% | 38.81% | -17.50% | 8.99% |
Shares Outstanding (Basic) | 125 | 125 | 125 | 126 | 128 | 130 |
Shares Outstanding (Diluted) | 125 | 125 | 125 | 126 | 128 | 130 |
Shares Change | 0.05% | -0.18% | -0.66% | -1.65% | -1.19% | -0.74% |
EPS (Basic) | 101.07 | 84.53 | 73.56 | 64.82 | 45.89 | 54.97 |
EPS (Diluted) | 101.02 | 84.51 | 73.53 | 64.77 | 45.89 | 54.96 |
EPS Growth | 29.63% | 14.94% | 13.52% | 41.14% | -16.50% | 9.79% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 5,441 | 1,640 | 8,393 | 6,327 | 6,176 | 4,129 |
Free Cash Flow Per Share | 43.52 | 13.13 | 67.05 | 50.21 | 48.20 | 31.84 |
Dividend Per Share | - | 28.000 | 28.000 | 36.000 | 7.000 | 6.333 |
Dividend Growth | - | 0% | -22.22% | 414.29% | 10.53% | 0% |
Gross Margin | 77.73% | 76.82% | 75.41% | 73.36% | 70.34% | 73.54% |
Operating Margin | 25.26% | 24.33% | 24.28% | 24.84% | 18.16% | 24.18% |
Profit Margin | 20.31% | 19.37% | 19.80% | 19.39% | 15.71% | 21.33% |
Free Cash Flow Margin | 8.75% | 3.01% | 18.06% | 15.03% | 16.50% | 12.36% |
EBITDA | 17,335 | 14,820 | 12,551 | 11,638 | 7,952 | 9,173 |
EBITDA Margin | 27.88% | 27.18% | 27.00% | 27.65% | 21.25% | 27.46% |
D&A For EBITDA | 1,632 | 1,554 | 1,267 | 1,181 | 1,154 | 1,094 |
EBIT | 15,703 | 13,266 | 11,285 | 10,457 | 6,798 | 8,079 |
EBIT Margin | 25.26% | 24.33% | 24.28% | 24.84% | 18.16% | 24.18% |
Effective Tax Rate | 25.17% | 23.35% | 22.60% | 26.73% | 21.10% | 21.64% |
Revenue as Reported | 64,113 | 56,249 | 47,426 | 42,933 | 38,413 | 34,567 |
Advertising Expenses | - | 6.5 | 57.6 | 44.9 | 50.2 | 47.8 |